NeuroProof — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NeuroProof is a neuroscience-focused CRO based in Göttingen, Germany, offering specialized pre-clinical screening services. Its core platform combines Microelectrode Array (MEA) recordings of neuronal network activity with advanced data analysis and pattern recognition to model neurological diseases and assess compound effects. The company serves pharmaceutical and biotech clients by providing phenotypic assays, neurotoxicity evaluations, and custom disease models, primarily using iPSC-derived neurons, to accelerate CNS drug development and reduce reliance on animal testing.

Alzheimer's DiseaseParkinson's DiseaseEpilepsyAmyotrophic Lateral SclerosisSchizophreniaNeuropathic PainFragile X SyndromeNeurotoxicity

Technology Platform

Microelectrode Array (MEA) neurochips for recording neuronal network activity, combined with AI/ML-driven spike train analysis and hyperexcitation pattern recognition. Utilizes primary rodent neurons and human induced pluripotent stem cell (iPSC)-derived neurons for functional phenotypic screening.

Opportunities

The growing demand for human-relevant, functional in vitro models in CNS drug discovery presents a major opportunity, as does the regulatory push for advanced neurotoxicity testing methods that reduce animal use.

Expansion of its iPSC-derived model portfolio for rare neurological diseases could open niche, high-value service segments.

Risk Factors

Revenue is tied to biopharma R&D budgets, which are cyclical and can lead to client spending cuts.

Technological competition from alternative platforms and the inherent risk that the company's models may not consistently predict clinical outcomes pose significant challenges.

Competitive Landscape

NeuroProof competes with other specialized electrophysiology CROs (e.g., Axion BioSystems' service division, Ncardia's services) and broader neuroscience CROs that offer molecular and cellular assays. Its key differentiator is the integrated combination of MEA, human iPSC-derived neurons, and proprietary AI-based analysis focused on network-level phenotypes.

More companies in Neuroscience & CNS →More companies in Germany →